| phase trial → CapableOf → evaluate efficacy | 0.65 | |
| phase trial → CapableOf → assess tolerability | 0.49 | |
| phase trial → CapableOf → assess pharmacokinetic | 0.42 | |
| phase trial → CapableOf → enrol patient | 0.41 | |
| phase trial → CapableOf → involve patient | 0.38 | |
| phase trial → CapableOf → recruit participant | 0.38 | |
| phase trial → CapableOf → use telemonitoring | 0.32 | |
| phase trial → CapableOf → evaluate cndo-109-activated all… | 0.25 | |
| phase trial → CapableOf → match patient | 0.25 |